Community-acquired pneumonia is the presence of signs and symptoms of lower respiratory tract infection acquired outside of the hospital.
The most common bacterial cause of childhood pneumonia is Streptococcus pneumoniae. It usually causes about 1/3 of radiographically-confirmed pneumonia in children <2 years of age.
Viruses commonly affect children <1 year of age than those aged >2 years, respiratory syncytial viruses (RSV) being the most frequently detected virus.
Mixed infection may occur in 8-40% of community-acquired pneumonia cases.
Treatment with intravenous or oral solithromycin is well-tolerated and leads to clinical improvement in most children and adolescents with community-acquired bacterial pneumonia (CABP), results of a recent study have shown.
An extended antibiotic course appears to be not any better than a standard course at achieving clinical cure among children hospitalized with community-acquired pneumonia (CAP) and at risk of chronic respiratory illnesses at 4 weeks, a study has shown.
Community-acquired severe pneumonia is more likely to develop in young boys and children with severe stunting, reports a recent study. Fever, illness duration, and a history of prior medical care are also important predictive factors for severe pneumonia.
Children with non-severe community-acquired pneumonia (CAP) may benefit from a 5-day antibiotic regimen compared with the current standard regimen of 10 days, according to results of the US-based SCOUT-CAP trial.
The occurrence of community-acquired pneumonia (CAP) in infancy, especially closer to preschool age, confers a heightened risk of developing subsequent chronic respiratory disorders, a study has found.
Urinary proadrenomedullin (proADM)/creatinine (Cr) ratio measured at the time of emergency department visit appears predictive of the development of severe outcomes in children with community-acquired pneumonia (CAP), with stronger discriminatory performance in radiographic disease, suggests a recent study.
A short-course high-dose amoxicillin regimen may be sufficient in treating children with community-acquired pneumonia (CAP) who do not require hospitalization, according to results of the SAFER* trial.
Despite a 90-percent cure rate after first treatment for children with acute lymphoblastic leukaemia (ALL), approximately 10–15 percent of patients with paediatric ALL will experience relapse. [Expert Rev Anticancer Ther 2017;17:725-736] A recent webinar on the current landscape of ALL highlighted the potential of immunotherapy for paediatric patients with relapsed or refractory ALL, thus providing hope for this high-risk patient group.